We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Tumor Markers Help Predict Response to Less Intensive HER2+ Chemotherapy

By LabMedica International staff writers
Posted on 07 Oct 2026

HER2-positive breast cancer is commonly treated before surgery with multiagent chemotherapy and HER2-targeted drugs. More...

In early-stage disease, a key challenge is identifying which tumors may respond well enough to allow treatment de-escalation. Pathologic complete response (pCR), defined as no invasive cancer in the breast or lymph nodes at surgery, is an important measure of response. New findings show that tumor markers and molecular testing may help identify patients likely to benefit from a less intensive approach.

ECOG-ACRIN Cancer Research Group investigators evaluated the CompassHER2-pCR clinical trial in patients with stage II–IIIA HER2-positive breast cancer. The treatment approach, known as THP, combined a single taxane chemotherapy drug with two HER2-targeted agents, trastuzumab and pertuzumab, for 12 weeks before surgery. Patients who achieved pathologic complete response (pCR) received no additional chemotherapy and continued dual HER2 blockade to complete one year of treatment.

Among 2,141 HER2-positive patients who began treatment, 43.8% achieved pCR. Response rates differed by hormone receptor status, reaching 63.7% in patients with estrogen receptor-negative (ER-) disease and 32.4% in those with estrogen receptor-positive (ER+) disease. Tumor characteristics associated with a greater likelihood of pCR included ER- or low estrogen receptor-expressing tumors, low or absent progesterone receptor expression, HER2 immunohistochemistry 3+ status, and treatment with weekly paclitaxel.

Researchers also evaluated HER2DX, a molecular test developed specifically for HER2-positive breast cancer, to determine whether it could further identify patients likely to respond to the de-escalated regimen. Diagnostic tumor samples from a representative subset of 569 participants were centrally analyzed using the validated and standardized HER2DX test, with results blinded to clinical outcomes. The pCR rate was 68% among tumors with high HER2DX pCR scores, compared with 19% among those with low scores. The difference between high and low scores exceeded 30 percentage points in both ER+ and ER-  disease.

The secondary results were published in the Journal of Clinical Oncology. CompassHER2-pCR is described as the largest prospective trial of 12-week neoadjuvant THP in stage II–IIIA HER2-positive breast cancer and the only trial in this setting powered to evaluate survival outcomes. The trial is continuing to follow patients with pCR to assess three-year recurrence-free survival, its primary endpoint.

“Our goal is not simply to give patients less treatment. It is to determine whether we can give each patient the treatment they need to achieve the best possible outcome while avoiding chemotherapy that may not be necessary. The recurrence-free survival results will be critical,” said Nadine Tung, medical oncologist at Beth Israel Deaconess Medical Center in Boston.

Related Links
ECOG-ACRIN Cancer Research Group


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.